Epinephrine induces von Willebrand factor release from cultured endothelial cells: Involvement of cyclic AMP-dependent signalling in exocytosis

Thrombosis and Haemostasis

Volumn 77, Issue 6, 1997, Pages 1182-1188

  Vischer, Ulrich M ^a   Wollheim, Claes B ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMO CYCLIC AMP; ADENYLATE CYCLASE; ADRENALIN; BETA ADRENERGIC RECEPTOR; BUCLADESINE; CALCIUM ION; CYCLIC AMP; DESMOPRESSIN; FORSKOLIN; FURA 2; HISTAMINE; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; PHOSPHODIESTERASE; PROPRANOLOL; THROMBIN; VON WILLEBRAND FACTOR;

ARTICLE; CALCIUM CELL LEVEL; CELL CULTURE; CELL GRANULE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXOCYTOSIS; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0030811329     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656135     Document Type: Article

References (29)

1. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European concerted action on thrombosis and disabilities angina pectoris study group: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995; 332: 635-41.
2. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
3. Wagner DD. Cell biology of von Willebrand factor. Ann Rev Cell Biol 1990; 6: 217-46.
4. Bowie EJW, Solberg LA, Fass DN, Johnson CM, Knutson GJ, Stewart ML, Zoecklein LJ. Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J Clin Invest 1986; 78: 26-30.
5. Birch KA, Pober JS, Zavoico GB, Means AR, Ewenstein BM. Calcium/calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothalial cells. J Cell Biol 1992; 118: 1501-10.
6. 2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. J Clin Invest 1987; 79: 600-8.
7. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor fron endothelial cells. J Clin Invest 1987; 79: 117-23.
8. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induces expression of P-selectin in endothelial cells. J Clin Invest 1994; 94: 1147-55.
9. Vischer UM, Jornot L, Wollheim CB, Theler JM. Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. Blood 1995; 85: 3164-72.
10. Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 1993; 154: 496-505.
11. Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest 1976; 57: 1618-25.
12. Eyster ME, Ballard JO, Prager D. Comparison of factor VIII levels after adrenalin in classic hemophilia and von Willebrand's disease. Thromb Haemost 1978; 39: 657-62.
13. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital anad acquired bleeding disorders. Blood 1988; 72: 1449-55.
14. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramina A, Brabet P, Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357: 333-6.
15. Lefkowitz RJ, Hoffman BB, Taylor P. Neurotransmission: The autonomie and somatic motor nervous systems. In: Goodman and Gilman's The pharmacologic basis of therapeutics. Hardman JG, Limbird LE (eds). 9th edition, McGraw-Hill, 1996; pp 105-39.
16. Jornot L, Junod AF. Variable glutathione levels and expression of anti-oxidant enzymes in human endothelial cells. Am J Physiol 1993; 264: L482-L9.
17. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
18. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46: 185-90.
19. Ullrich S, Wollheim CB: Expression of both α1- and α2-adrenoceptors in an insulin-secreting cell line. Molec Pharmacol 1985; 28:100-6.
20. 2+ in the secretion of von Willebrand factor from human vascular endothelial cells. Biochem J 1992; 296: 631-5.
21. Ämmälä C, Ashcroft FM, Rorsman P. Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells. Nature 1993; 363: 356-8.
22. Birch K, Ewenstein BM, Golan DE, Pober JS. Prolonged peak elavations in cytosolic free calcium ions, derived from intracellular stores, correlate with the extent of thrombin-stimulated exocytosis in single human umbilical vein endothelial cells. J Cell Physiol 1994; 160: 545-54.
23. Vajanaphanich M, Schultz C, Tsien RY, Traynor-Kaplan AE, Pandol SJ, Barrett KE. Cross-talk between calcium and cAMP-dependent intracellular signaling pathways. J Clin Invest 1995; 96: 386-93.
24. Ämmälä C, Eliasson L, Bokvist K, Berggren PO, Honkanen RE, Sjöholm A, Rorsman P. Activation of protein kinases and inhibition of protein phosphatases play a central role in the regulation of exocytosis in mouse pancreatic β-cells. Proc Natl Acad Sci USA 1994; 91: 4343-7.
25. Loesberg C, Gonsalves MD, Zandbergen J, Willems C, van Aken WG, Stel HV, de Groot PG. The effect of calcium on the secretion of factor VIII-related antigen by cultured human endothelial cells. Biochim Biophys Acta 1983; 763: 160-8.
26. Tranquille N, Emeis JJ. The role of cyclic nucleotides in the release of tissue-type plasminogen activator and von Willebrand factor. Thromb Haemost 1993; 69: 259-61.
27. Rhodes CJ, Halban PA. Newly synthesized proinsulin/insulin and stored insulin are released from pancreatic B cells predominantly via a regulated, rather than a constitutive, pathway. J Cell Biol 1987; 105: 145-53.
28. McCarroll DR, Ruggeri ZM, Montgomery RR. Correlation between circulating levels of von Willebrand's antigen II and von Willebrand factor: discrimination between type I and Type II von Willebrand's disease. J Lab Clin Med 1984; 103: 704-11.
29. Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmle B. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993; 90: 7503-7.